Tag : CD47 Antigen / metabolism*

Harnessing CD47 mimicry to inhibit phagocytic clearance and enhance anti-tumor efficacy of nanoliposomal doxorubicin.

NewsemiaJanuary 13, 2021

by NewsemiaJanuary 13, 2021012

Related Articles Harnessing CD47 mimicry to inhibit phagocytic clearance and enhance anti-tumor efficacy of nanoliposomal doxorubicin. Expert Opin Drug Deliv. 2020 07;17(7):1049-1058 Authors: Gheibi Hayat...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

CORONA (COVID-19) Live Stats

UW–Madison tool aids in equitable vaccine distribution

Controlling chemical catalysts with sculpted light

[How I explore… protrusio acetabuli in children].

ARES IV: Probing the Atmospheres of the…

The R-Loop Atlas of Arabidopsis Development and…

Targeted cutaneous delivery of etanercept using Er:YAG…

Merit-based Incentive Program Data Submission for 2020

Blood pressure targets in adults with hypertension.

New patent for Vertex Pharms drug TRIKAFTA…

Lipidome-based rapid diagnosis with machine learning for…

Newsemia

Tag : CD47 Antigen / metabolism*

Harnessing CD47 mimicry to inhibit phagocytic clearance and enhance anti-tumor efficacy of nanoliposomal doxorubicin.